News

Increase Flow Rate if Cluster Patients Don't Respond to Oxygen


 

LAS VEGAS — The flow rate of oxygen routinely prescribed to abort cluster migraine is too low to be effective in many patients, Todd D. Rozen, M.D., said at a symposium sponsored by the American Headache Society.

Clinicians typically prescribe flow rates of 7–10 L/min, said Dr. Rozen of the Michigan Head-Pain and Neurological Institute in Ann Arbor. About 30% of patients fail to respond to flow rates in this range.

Dr. Rozen described three patients whose headaches were apparently refractory to oxygen but who all responded well when the flow rate was pushed to 15 L/min—about the maximum flow rate delivered by most medical-grade oxygen regulators (Neurology 2004;63:593).

“I'm now telling my patients that you're not resistant to oxygen until you try 15 L/min,” Dr. Rozen said.

There are a number of caveats regarding oxygen therapy for cluster headache. The gas must be delivered through a nonrebreather face mask, and patients must be cautioned strongly about the highly flammable nature of pure oxygen. In addition, the higher flow rates may be dangerous in patients with chronic obstructive pulmonary disease.

Oxygen is thought to exert its effect on cluster headaches through cerebral arterio- and vasoconstriction. Many people whose headaches appear refractory to oxygen therapy are smokers; according to the pulmonary literature, smokers exhibit less vasoconstriction in response to 100% oxygen than do nonsmokers.

Dr. Rozen hypothesized that in some individuals, a higher oxygen flow rate is needed to obtain a clinically meaningful degree of vasoconstriction.

The goal of abortive treatment is to stop the pain within 10–15 minutes.

Oxygen therapy is a good choice for patients whose cardiovascular risk factors render them unsuitable candidates for injected sumatriptan. “I don't know how many times I've seen cluster patients who have never tried oxygen,” Dr. Rozen said.

Recommended Reading

Acupuncture Nearly Halves Headache Days
MDedge Neurology
Pediatric Migraine Guidelines Decry Lack of Data on Kids
MDedge Neurology
Synthetic Marine Snail Toxin Gets FDA Approval as Intrathecal Analgesic
MDedge Neurology
New Agent Approved for Two Neuropathic Pain Conditions
MDedge Neurology
Nerve Damage Less With Sentinel Node Biopsy
MDedge Neurology
Spinal Triage System Culls Candidates for Surgery
MDedge Neurology
Minimally Invasive Surgery an Option For Patients With Trigeminal Neuralgia
MDedge Neurology
Brain May Modulate Chronic Low Back Pain
MDedge Neurology